SecBot SecBot
144 ·Filed Oct 30, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
NEUTRAL
Impact 1/10
Horizonimmediate Processed17d 10h ago SEC0001950047-26-010505
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is de minimis and carries no material signal. Monitor for any larger insider sales or changes in director holdings in future Form 4 filings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$145.35
T+0 close · Oct 30, 2026 · via day close
Latest settled
+16.17%
T+5 · $168.86 · next T+20 in 14d
Vs SPY
+16.10%
α at T+5
Latest observation
+14.39%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $145.35entry
  2. T+1 · 14d ago +13.42%α +13.12% · $164.85
  3. T+5 · 8d ago +16.17%α +16.10% · $168.86
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director George J. Morrow filed a Form 144 notice of intent to sell 300 shares of Neurocrine Biosciences common stock, valued at approximately $43,914 based on the filing date. The shares were acquired through option exercise on the same date. The proposed sale is very small relative to the company's $14.8B market cap and represents a routine insider transaction.

Key Facts

  • Director George J. Morrow filed Form 144 to sell 300 shares of NBIX common stock.
  • Estimated value of proposed sale: $43,914 (based on filing date).
  • Shares were acquired via option exercise on 10/30/2026.
  • Sale is immaterial relative to NBIX's $14.8B market cap.
  • Form 144 signals intent to sell; the sale may not occur.

Financial Impact

Proposed sale of 300 shares worth ~$43,914, less than 0.0003% of market cap.

dilution

Risk Factors

  • Form 144 is only an intent to sell; the transaction may not be executed.
  • No additional context on the insider's total holdings is provided in the filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (37 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010505
Document: 0001950047-26-010505-index.html0001950047-26-010505
Document: 0001950047-26-010505.txt0001950047-26-010505

Track record

30 reports on NBIX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  3. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  4. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  5. Nov 2, 202614d ago Press Release Bullish 6/10 No price data
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  8. Oct 30, 202617d ago 144 Neutral 1/10 Viewing Entry $145.35 Now $165.31 +13.73% settles Dec 1
  9. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
Showing 10 of 30

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026